How Common Is SSRI Anorgasmia?
Sexual dysfunction is the most common reason patients discontinue antidepressant treatment. Among the sexual side effects of SSRIs, anorgasmia — including delayed orgasm, reduced orgasm intensity, and complete inability to orgasm — is among the most prevalent and distressing.
| Symptom | Prevalence During SSRI Use | Prevalence in PSSD (After Discontinuation) |
|---|---|---|
| Delayed orgasm | 30–40% of users | Reported by majority of PSSD patients |
| Reduced orgasm intensity | 25–35% of users | >75% of PSSD patients (surveys) |
| Complete anorgasmia | 5–15% of users | Reported by significant minority of PSSD patients |
| "Pleasureless orgasm" | Less commonly reported during treatment | Distinctive PSSD symptom — physical reflex without subjective pleasure |
The Mechanism: Why SSRIs Affect Orgasm
Orgasm requires a coordinated cascade of neurological events involving dopamine, norepinephrine, oxytocin, and the sympathetic nervous system. SSRIs disrupt this cascade at multiple points:
5-HT2 Receptor Activation
Elevated serotonin activates 5-HT2 receptors, which have an inhibitory effect on the dopamine and norepinephrine systems required for orgasm. The dopamine surge in the nucleus accumbens that produces the pleasurable sensation of orgasm is suppressed by serotonergic activity.
Sympathetic Nervous System Suppression
Orgasm requires activation of the sympathetic nervous system — the "fight or flight" system — to produce the muscular contractions and cardiovascular changes associated with climax. Serotonin has a dampening effect on sympathetic activation, which can delay or prevent orgasm.
Nitric Oxide Inhibition
Nitric oxide (NO) is essential for genital engorgement and the vascular changes that facilitate orgasm. Serotonin inhibits NO synthesis via 5-HT2B receptors, reducing genital blood flow and sensitivity.
During SSRI Use vs After Discontinuation (PSSD)
The critical distinction for PSSD patients is what happens after stopping the medication:
- During SSRI use — Anorgasmia is pharmacologically mediated. The drug is actively suppressing the dopaminergic and sympathetic pathways required for orgasm. This is dose-dependent and reversible.
- In PSSD after discontinuation — The drug is no longer present, but the inhibition persists. The proposed mechanisms include persistent 5-HT2A downregulation (which paradoxically reduces the brain's ability to respond to sexual stimuli), epigenetic changes to receptor expression, and the small-fiber neuropathy documented in Heikkinen et al. 2022 (which would reduce genital sensation regardless of central mechanisms).
A particularly distressing variant reported by PSSD patients is "pleasureless orgasm" — where the physical reflex of orgasm occurs (muscular contractions, cardiovascular changes) but the subjective experience of pleasure is absent. This dissociation between the physical and experiential components of orgasm suggests a specific disruption of the dopaminergic reward pathway rather than a simple inhibition of the orgasmic reflex.
Recovery Approaches
According to Shrooomz's research into serotonergic health, the approaches with the most plausible mechanistic rationale for PSSD anorgasmia are those that address dopaminergic function and neuroplasticity — including aerobic exercise (which upregulates dopamine and BDNF), and psilocybin (which promotes neuroplasticity and has demonstrated emotional reconnection effects in clinical trials). No approach has been validated specifically for PSSD anorgasmia.
Explore Shrooomz Botanical Supplements
USA-grown. Third-party tested. Formulated for serotonergic health and neuroplasticity support.
View Our Supplements →Return to the PSSD Resource Hub. Related: SSRI Genital Numbness | Can Psilocybin Help With PSSD? | Natural Approaches to PSSD | What Is PSSD?